Commercial Law - Consumer Protections - Health Care Financing
SB 796 creates a new subtitle in Maryland’s Commercial Law Article establishing consumer protections for health care financing arrangements, especially when patients are offered or use third-party financing such as credit cards, loans, or lines of credit to pay for medical or veterinary care. The bill requires health care providers to give patients a written disclosure and a written treatment plan before discussing third-party financing, and it requires providers to give a full refund for any treatment not provided within 15 days of a patient’s request. It also requires the Consumer Protection Division of the Attorney General’s Office to prepare and publish a standardized disclosure explaining that credit-card payments for health care are not treated as health care debt and may not receive the same legal protections.
The bill prohibits providers and their employees or agents from obtaining financing on a patient’s behalf, completing applications for patients, giving patients devices to apply, or promoting financing to patients who are under anesthesia, actively being treated, or located in treatment areas. It also bars providers from offering or accepting third-party financing, or charging a health care credit card, when insurance will cover the services, except to pay copays, coinsurance, or deductibles. Providers may not bill a third-party financier more than 30 days before the services are provided, and the bill allows the Attorney General to adopt implementing regulations. Violations are treated as unfair, abusive, or deceptive trade practices under Title 13, making them subject to existing consumer protection enforcement and penalties.
The bill’s impact on state law is to add a new set of disclosure, refund, and marketing rules governing health care financing transactions and to expand the list of practices deemed deceptive under Maryland consumer protection law. It would affect health care providers, their employees and agents, patients seeking elective or covered care, lenders and credit-card issuers involved in medical financing, and the Attorney General’s Consumer Protection Division. It also specifically addresses patients covered by the Maryland Health Care Assistance Program by requiring treatment plans to identify covered alternatives and the patient’s right to request only covered services.
Because no committee transcripts or votes were provided, there is no recorded legislative debate or voting history to gauge formal support or opposition. Based on the bill text alone, the measure appears consumer-protection oriented and designed to increase transparency and reduce pressure on patients to use financing at the point of care. The overall sentiment suggested by the bill’s structure is protective of patients, especially around informed consent, billing timing, and the risks of using credit for medical expenses.
The main points of contention likely concern the scope of restrictions on provider-patient financing discussions and the operational burden on providers, particularly the limits on promoting financing, the timing restriction on billing financiers, and the requirement to provide detailed disclosures and treatment plans. Another possible issue is the bill’s treatment of health care credit-card debt as distinct from health care debt, which may reduce consumer protections and could be viewed as either a necessary warning or an unfavorable shift depending on perspective.
SB 796 would add Subtitle 51 to the Commercial Law Article and amend the unfair trade practices statute to make violations of the new health care financing rules actionable under Maryland’s consumer protection framework. It would impose new disclosure, refund, and timing requirements on health care providers, restrict provider involvement in third-party financing applications and promotions, and require the Attorney General’s Consumer Protection Division to publish a standardized disclosure. The bill would also affect how medical financing interacts with insurance coverage and Maryland Medicaid, and it would apply to both human health care providers and veterinarians, while excluding hospitals from the definition of provider for this subtitle.
No committee discussion or vote data was provided, so there is no direct evidence of legislative support or opposition in the record supplied. The bill text reflects a consumer-protection approach focused on patient awareness, informed choice, and limiting potentially coercive financing practices in medical settings. Overall, the measure appears favorable to patients and consumer advocates, with its design suggesting concern about surprise debt, pressure sales tactics, and the loss of legal protections when medical bills are converted into credit-card or loan obligations.
Likely areas of contention include whether the bill goes too far in restricting how providers may discuss financing options, especially the prohibitions on assisting with applications, using devices to apply, and promoting financing in treatment areas or while patients are under anesthesia. Providers and lenders may also object to the 30-day billing restriction, the mandatory refund timeline, and the administrative burden of preparing and delivering detailed treatment plans and disclosures. On the other hand, consumer advocates would likely support the bill’s warnings about interest, credit reporting, and the loss of health-care-debt protections when patients use credit cards to pay medical bills.